2024-517644-62-00Active, not recruitingPhase 1
Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 16 Oct 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 6 Feb 2025
- Start date
- 30 Jun 2025
- Lead sponsor
- Janssen Cilag International
- Diseases
- Asthma
- EU CT number
- 2024-517644-62-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 46
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SGS Belgium | Edegem | Belgium | Active, not recruiting |
| Charite Research Organisation GmbH | Berlin | Germany | Active, not recruiting |
| IKF Pneumologie GmbH & Co. KG | Frankfurt am Main | Germany | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.